Q1 Earnings Forecast for argenx Issued By William Blair

argenx SE (NASDAQ:ARGX - Free Report) - Equities researchers at William Blair issued their Q1 2026 earnings per share estimates for shares of argenx in a research note issued to investors on Monday, March 17th. William Blair analyst M. Minter expects that the company will post earnings of $6.06 per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for argenx's current full-year earnings is $3.13 per share. William Blair also issued estimates for argenx's Q2 2026 earnings at $6.23 EPS and Q3 2026 earnings at $7.02 EPS.

Several other equities analysts have also issued reports on ARGX. Guggenheim lifted their target price on shares of argenx from $775.00 to $1,100.00 and gave the company a "buy" rating in a report on Monday, March 10th. Sanford C. Bernstein upgraded shares of argenx from a "market perform" rating to an "outperform" rating in a report on Monday. Oppenheimer lifted their target price on shares of argenx from $675.00 to $704.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Wells Fargo & Company lifted their target price on shares of argenx from $723.00 to $741.00 and gave the company an "overweight" rating in a report on Friday, February 28th. Finally, HC Wainwright boosted their price objective on shares of argenx from $717.00 to $720.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, argenx has an average rating of "Moderate Buy" and an average target price of $687.00.

Remove Ads

argenx Stock Down 1.1 %

Shares of ARGX stock traded down $6.93 during trading hours on Wednesday, hitting $613.04. 176,725 shares of the company's stock traded hands, compared to its average volume of 284,507. The stock's fifty day simple moving average is $635.52 and its two-hundred day simple moving average is $598.47. argenx has a 12-month low of $352.77 and a 12-month high of $678.21. The stock has a market cap of $37.25 billion, a price-to-earnings ratio of -696.64 and a beta of 0.59.

argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analysts' expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. GeoWealth Management LLC lifted its position in argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after purchasing an additional 18 shares during the period. Steward Partners Investment Advisory LLC lifted its position in argenx by 5.6% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company's stock valued at $234,000 after purchasing an additional 20 shares during the period. SG Americas Securities LLC lifted its position in argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company's stock valued at $220,000 after purchasing an additional 21 shares during the period. Farther Finance Advisors LLC lifted its position in argenx by 38.2% during the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock valued at $47,000 after purchasing an additional 21 shares during the period. Finally, Dynasty Wealth Management LLC raised its position in shares of argenx by 3.4% in the fourth quarter. Dynasty Wealth Management LLC now owns 677 shares of the company's stock worth $416,000 after acquiring an additional 22 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.